Tuesday, February 18, 2014 1:37:33 PM
Flucide 500X better than Oseltamivir(Tamiflu)
It's clearly shown in the research: the reduction in viral load (the number of viruses circulating in the bloodstream) was 1,000 times reduced (whereas Oseltamivir(Tamiflu) reduced it a mere 2 times).
In other words the receptors on FluCide work EXTREMELY well at trapping the viruses.
It's not the ligands (the molecules that attach to the rectors) but the receptors themselves that are important.
It is very well established what receptors are important in what diseases. (thats' why they know that the CCR5 and CXCR4 receptors are very important in HIV, for example)
ALL infectious disease that are intracellular (infect INSIDE cells) must use some receptor to enter the cells. By using the specific receptors that a specific disease must use, a nanoviricide could work for any intracellular infectious disease. I suspect the reason they are working on viral targets first is that's the area where there are no effective drugs (because of viruses ability to mutate around any drug EXCEPT one that traps it by using a receptor it MUST attach to to infect. "First pick the low hanging fruit." (and "low hanging" inclused areas where there is no competition>)
It's clearly shown in the research: the reduction in viral load (the number of viruses circulating in the bloodstream) was 1,000 times reduced (whereas Oseltamivir(Tamiflu) reduced it a mere 2 times).
In other words the receptors on FluCide work EXTREMELY well at trapping the viruses.
It's not the ligands (the molecules that attach to the rectors) but the receptors themselves that are important.
It is very well established what receptors are important in what diseases. (thats' why they know that the CCR5 and CXCR4 receptors are very important in HIV, for example)
ALL infectious disease that are intracellular (infect INSIDE cells) must use some receptor to enter the cells. By using the specific receptors that a specific disease must use, a nanoviricide could work for any intracellular infectious disease. I suspect the reason they are working on viral targets first is that's the area where there are no effective drugs (because of viruses ability to mutate around any drug EXCEPT one that traps it by using a receptor it MUST attach to to infect. "First pick the low hanging fruit." (and "low hanging" inclused areas where there is no competition>)
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
